Related Experiment Video
Updated: Aug 12, 2026

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
Published on: September 10, 2018
A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy
Marina E Kirkland1,2, Stephanie Patfield1, Anna C Hughes1
1United States Department of Agriculture, Agricultural Research Service, Western Regional Research Center , Albany, California, USA.
Abstract:
Shiga toxin-producing Escherichia coli infections are difficult to treat due to the risk of antibiotic-induced stress upregulating the production of toxins, medical treatment is consequently limited to supportive care to prevent the development of hemolytic uremic syndrome (HUS). Here, we introduce a potentially therapeutic humanized mouse monoclonal antibody (Hu-mAb 2-5) targeting Stx2a, the most common Shiga toxin subtype identified from outbreaks. We demonstrate that Hu-mAb 2-5 has low immunogenicity in healthy adults ex vivo and high neutralizing efficacy in vivo, protecting mice from mortality and HUS-related tissue damage.
Related Concept Videos
Tumor Immunotherapy
Acute Pyelonephritis II: Diagnostic Studies and Management
Bacterial Gastroenteritis
Genital Herpes
Inhibitors of Viral Protein Synthesis

